Astrazeneca dived 11.1 per cent after turning down Pfizer’s 55 pounds/share take-it-or-leave-it offer.
That steep decline was the biggest drag on the FTSE 100 by some margin, with the index closing down 11.26 points, or 0.2 per cent, at 6,844.55 points.
Astrazeneca had risen more than 27 per cent in the month since the first Pfizer bid was reported, and traders said that a deal was now unlikely after Pfizer appeared reluctant to engage in a hostile approach.
“With Pfizer saying they won’t go hostile, it looks like it is pretty much dead,” Will Hedden, sales trader at IG, said.
“The rhetoric from certain government sections about securing jobs in the UK will have been a hurdle and certainly put off Astrazeneca shareholders.”
Recent price moves had left Astrazeneca trading at a forward price/EPS multiple of 19.5, according to StarMine data, compared to 15.5 for Glaxosmithkline and 14.3 for Sanofi , and over double its 10-year median of 9.3.
But following yesterday’s share price pull-back, Citi took the opportunity to add Astrazeneca to its Focus List Europe.
It reckoned the market still under-appreciated Astrazeneca’s portfolio in both immune-oncology and the management of auto-immune related disease.
The FTSE 100 retraced some of the previous week’s 0.6 per cent gain, which saw it touch 14-year highs. On Thursday it came within 0.8 per cent of all-time highs set in December 1999.
“With the FTSE 100 close to all-time-high territory, concerns have once again been raised in relation to valuation, which is creating something of a headwind,” said Jeremy Batstone-Carr, analyst at Charles Stanley.
In common with Astrazeneca, the broader market is also trading above long-run average valuations. The FTSE 100 trades at a price to earnings ratio of 13.8, compared to a 10-year average of 11.8, Thomson Reuters Datastream showed.
The top two risers were airlines EasyJet, up 4.7 per cent, and International Consolidated Airlines, up 3.5 per cent, as forecast-beating results from Irish peer Ryanair buoyed the sector.